Casper Hansen
Amministratore Delegato presso Pcovery ApS
Provenienza dei contatti di primo grado di Casper Hansen
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.
3
| Operating Division | Investment Managers | 3 |
Embark Laboratories ApS
Embark Laboratories ApS BiotechnologyHealth Technology Embark Laboratories ApS is a Danish biotech company that focuses on cardiometabolic disease. The private company is based in Copenhagen, Denmark. The company was founded in 2023. Casper Tind Hansen has been the CEO of the company since 2023.
2
| Private Company | Biotechnology | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Casper Hansen tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
University of Copenhagen | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Celltrix AB
Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal Corporate Officer/Principal | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member Chairman | |
Omnes Capital SAS /Venture/
Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Investment Managers | Private Equity Investor | |
Cardeas Pharma Corp.
Cardeas Pharma Corp. Pharmaceuticals: MajorHealth Technology Cardeas Pharma Corp. develops drugs for the prevention of ventilator associated pneumonia. It offers a novel antibiotic formulation of two drugs with synergistic activity against relevant, resistant Gram-negative bacilli, including pseudomonas aeruginosa, acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae. The company was founded by Alan Bruce Montgomery on November 23, 2011 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
Danmarks Farmaceutiske Universitet | College/University | Doctorate Degree | |
7TM A/S
7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Founder | |
University of Aarhus | College/University | Doctorate Degree | |
Dansk Vækstkapital II K/S
Dansk Vækstkapital II K/S Investment ManagersFinance Dansk Vækstkapital II K/S is a fund of funds targeting unlisted private equity and venture funds in Scandinavia. It invest in funds with a minimum size of DKK 400 million to DKK 500 million. The fund focuses on venture and equity funds that invest in companies with up to 1000 employees and DKK 1,25 million in revenue. | Investment Managers | Chairman | |
Practio ApS
Practio ApS Medical/Nursing ServicesHealth Services Practio ApS offers vaccination and medical consultancy services. It's offerings include vaccines for Yellow fever, Rabies, Typhoid, Hepatitis A and B, Meningitis, Cholera, and Measles, mumps, and rubella. The company was founded on September 29, 2014 and is headquartered in Copenhagen, Denmark. | Medical/Nursing Services | Chairman | |
InnoCon Medical ApS
InnoCon Medical ApS Medical SpecialtiesHealth Technology InnoCon Medical is a privately owned Danish medical device company that was founded in 2017. The company is based in Aalborg, Denmark. InnoCon Medical develops a neuromodulation healthcare solution for people with incontinence. Jesper Nielsen has been the CEO of the company since 2017. | Medical Specialties | Director/Board Member | |
Reapplix A/S
Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | Medical Distributors | Chairman | |
Novo Ventures (US), Inc.
Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Private Equity Investor | |
Syddansk Innovation A/S
Syddansk Innovation A/S Investment ManagersFinance Syddansk Innovation A/S (SDI) is a Danish venture capital firm funded by the Government of Denmark. The firm was established in 1998 by joining the two innovation environments Teknologisk Innovation A/S and Syddansk Innovation A/S, and is headquartered in Odense, Denmark. | Investment Managers | Chairman | |
Neurescue ApS
Neurescue ApS Medical SpecialtiesHealth Technology Neurescue ApS develops innovative medical devices for the treatment of cardiac arrest. It offers new platform of treatment methods for paramedics, nurses and doctors alike. The company was founded by Habib Frost in 2013 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Director/Board Member | |
Novo Principal Investments
Novo Principal Investments Investment ManagersFinance Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | President | |
Archimedes Pharma Ltd.
Archimedes Pharma Ltd. Pharmaceuticals: MajorHealth Technology Archimedes Pharma Ltd. operates as a holding company with interests in pharmaceuticals. The company was founded by Richard Anthony de Souza, Charles Marchetti and Michael Clark on December 9, 2004 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
BioAim LLC | Founder | ||
Elion Oncology, Inc.
Elion Oncology, Inc. Pharmaceuticals: MajorHealth Technology Elion Oncology, Inc. engages in the provision of pharmaceutical services. The company was founded in 2016 and is headquartered in Bethesda, MD. | Pharmaceuticals: Major | Director/Board Member | |
PROCESSA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
ALLAKOS INC. | Pharmaceuticals: Major | Chairman | |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CRI Worldwide LLC
CRI Worldwide LLC Miscellaneous Commercial ServicesCommercial Services CRI Worldwide LLC engages in the provision of inpatient and outpatient clinical research services. It specializes in inpatient and outpatient clinical trials ranging from phase I to IV focusing on pediatrics, adolescents, adults, and elderly in the areas of acute and chronic pain, attention deficit hyperactivity disorder, Alzheimer’s disease, atypical depression, back pain, bipolar disorder, cancer pain, diabetes, epilepsy, fibromyalgia, general anxiety disorder, hepatitis, major depressive disorder, manic depression, migraines/headaches, mild cognitive impairment. The company was founded by Howard A. Hassman in 2000 and is headquartered in Mt. Laurel, NJ. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Contera Pharma ApS
Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
Conrig Pharma ApS
Conrig Pharma ApS Pharmaceuticals: MajorHealth Technology Conrig Pharma ApS provides drug for oral treatment of atopical disease. Its new drug (CRG-010) is use for topical treatment of itch/pruritus associated with atopical dermatitis. The company was founded by John Bondo Hansen and Mikael Sondergaard Thomsen on December 20, 2010 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
Konticon Consulting, Inc. | Chief Executive Officer | ||
Sound Biotechnology, Inc. | Founder | ||
Aurigene Discovery Technologies Ltd.
Aurigene Discovery Technologies Ltd. BiotechnologyHealth Technology Aurigene Discovery Technologies Ltd. operates as biotechnology company. It offers research services such as integrated research and stand-alone research. The company is headquartered in Bangalore, India. | Biotechnology | Director/Board Member | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal | |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Cardior Pharmaceuticals GmbH
Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance Boehringer Ingelheim (BIVF) is the venture capital arm of Boehringer Ingelheim International GmbH, itself a subsidiary of C.H. Boehringer Sohn AG & Co. KG. The firm was founded in 2010 and is headquartered in Ingelheim, Germany. It also has two US offices located in Fremont, California, and Cambridge, Massachusetts. | Investment Managers | Private Equity Investor | |
GT Gain Therapeutics SA
GT Gain Therapeutics SA Pharmaceuticals: MajorHealth Technology GT Gain Therapeutics SA operates as a preclinical stage biotech firm developing a class of next generation brain-penetrant non-competitive pharmacological chaperones for the treatment of devastating diseases using the proprietary SEE-Tx technology. Its projects include Beta-galactosidase GLB1 gene and Glucosylceramidase GBA gene. The company was founded by Lorenzo Leoni and is headquartered in Lugano, Switzerland. | Pharmaceuticals: Major | Chairman | |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Director/Board Member | |
ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Yale University | College/University | Doctorate Degree | |
Viewpoint Therapeutics, Inc.
Viewpoint Therapeutics, Inc. BiotechnologyHealth Technology Viewpoint Therapeutics, Inc. operates as a biotechnology company. It prevents and treats cataracts and presbyopia, and protein misfolding. The company was founded by Leah Makley in July of 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member |
Statistiche
Distribuzione geografica
Danimarca | 21 |
Stati Uniti | 18 |
Germania | 4 |
Svizzera | 3 |
Regno Unito | 3 |
Settori
Health Technology | 31 |
Finance | 8 |
Consumer Services | 6 |
Commercial Services | 3 |
Transportation | 2 |
Posizioni
Director/Board Member | 58 |
Chairman | 27 |
Corporate Officer/Principal | 22 |
Founder | 15 |
Private Equity Investor | 8 |
Contatti più connessi
- Borsa valori
- Insiders
- Casper Hansen
- Connessioni Società